CJC-1295 Research Peptides

Compare CJC-1295 research products by exact form, labelled quantity, price per mg, testing evidence and product transparency. Read what the human DAC studies actually show, why no-DAC products must be kept separate, and what remains unknown about clinical outcomes.

Research-use products only. Not presented as supplements, medicines, or products for human or veterinary consumption.

3products compared

2labelled quantities

£4.00 – £20.00per mg

0with verified testing evidence

Top Picks

Best Overall

Quantity: 10 mg / vial
Form: No DAC

£4.00per mg

£40.00per pack

View Analysis Buy Now

Product & testing details

Supplier: Reta Research
Vials per pack: 1
Price per vial: £40.00
Listing last checked: 2026-09-20 09:20:11

Evidence status: Testing claimed
Manufacturer statement: "Lyophilised powder, 10mg vial, ≥99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity by HPLC, Certificate of Analysis on request." / "Research-grade peptides, independently HPLC-tested" / "Independent Certificates of Analysis, published for every lot we ship."
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-20

CJC 1295 No DAC 10mg

Reta Research

£4.00per mg

£40.00per pack

View Analysis Buy Now

Best Tested

Quantity: 10 mg / vial
Form: No DAC

£4.00per mg

£40.00per pack

View Analysis Buy Now

Product & testing details

Supplier: Reta Research
Vials per pack: 1
Price per vial: £40.00
Listing last checked: 2026-09-20 09:20:11

Evidence status: Testing claimed
Manufacturer statement: "Lyophilised powder, 10mg vial, ≥99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity by HPLC, Certificate of Analysis on request." / "Research-grade peptides, independently HPLC-tested" / "Independent Certificates of Analysis, published for every lot we ship."
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-20

CJC 1295 No DAC 10mg

Reta Research

£4.00per mg

£40.00per pack

View Analysis Buy Now

Lowest Price per mg

Quantity: 10 mg / vial
Form: No DAC

£4.00per mg

£40.00per pack

View Analysis Buy Now

Product & testing details

Supplier: Reta Research
Vials per pack: 1
Price per vial: £40.00
Listing last checked: 2026-09-20 09:20:11

Evidence status: Testing claimed
Manufacturer statement: "Lyophilised powder, 10mg vial, ≥99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity by HPLC, Certificate of Analysis on request." / "Research-grade peptides, independently HPLC-tested" / "Independent Certificates of Analysis, published for every lot we ship."
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-20

CJC 1295 No DAC 10mg

Reta Research

£4.00per mg

£40.00per pack

View Analysis Buy Now

Compare research products

Form

Vial size

Research peptide product comparison
#	Product	Quantity	Form	Price / vial	Price / mg	Testing	Score
1	CJC 1295 No DAC 10mgReta Research	10 mg / vial	No DAC	£40.00per vial	£4.00per mg	Testing evidence Evidence status Testing claimed Manufacturer statement "Lyophilised powder, 10mg vial, ≥99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity by HPLC, Certificate of Analysis on request." / "Research-grade peptides, independently HPLC-tested" / "Independent Certificates of Analysis, published for every lot we ship." Laboratory Not recorded Certification body Not recorded Batch Not recorded Batch-specific report Not established in this record Report date Not recorded Evidence checked 2026-09-20	Why this score? Testing & analytical evidence 12/45 Value 16/25 Product identity 12/15 Supplier transparency 10/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now
2	CJC-1295 (with DAC) 2 mgUK Peptides (ukpeptides.com)	2 mg / vial	With DAC	£39.99per vial	£20.00per mg	Testing evidence Evidence status Testing claimed Manufacturer statement 99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa}+ HPLC purity · batch COA; independently verified by HPLC and LC-MS before release; LC-MS confirmed; residual moisture < 3.0{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} (Karl Fischer); every batch tested; third-party verified 99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity. Laboratory Not recorded Certification body Not recorded Batch Not recorded Batch-specific report Not established in this record Report date Not recorded Evidence checked 2026-09-20	Why this score? Testing & analytical evidence 10/45 Value 12/25 Product identity 12/15 Supplier transparency 3/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now
3	CJC-1295 (No DAC) 2 mgUK Peptides (ukpeptides.com)	2 mg / vial	No DAC	£39.99per vial	£20.00per mg	Testing evidence Evidence status Testing claimed Manufacturer statement "99.8{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} HPLC verified"; "Specifications for this compound, independently verified by HPLC and LC-MS before release."; "Every batch is sent to an independent accredited lab for HPLC purity and LC-MS identity testing before it's released." Laboratory Not recorded Certification body Not recorded Batch Not recorded Batch-specific report Not established in this record Report date Not recorded Evidence checked 2026-09-20	Why this score? Testing & analytical evidence 10/45 Value 0/25 Product identity 11/15 Supplier transparency 3/10 Label & listing transparency 5/5 Displayed points and weights are rounded; the total uses unrounded weights. Pending dimensions are excluded. Provisional scores may change after review.	Buy Now

Quantity: 10 mg / vial
Form: No DAC

£4.00per mg

£40.00per pack

View Analysis Buy Now

Product & testing details

Supplier: Reta Research
Vials per pack: 1
Price per vial: £40.00
Listing last checked: 2026-09-20 09:20:11

Evidence status: Testing claimed
Manufacturer statement: "Lyophilised powder, 10mg vial, ≥99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity by HPLC, Certificate of Analysis on request." / "Research-grade peptides, independently HPLC-tested" / "Independent Certificates of Analysis, published for every lot we ship."
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-20

Quantity: 2 mg / vial
Form: With DAC

£20.00per mg

£39.99per pack

View Analysis Buy Now

Product & testing details

Supplier: UK Peptides (ukpeptides.com)
Vials per pack: 1
Price per vial: £39.99
Listing last checked: 2026-09-20 09:20:11

Evidence status: Testing claimed
Manufacturer statement: 99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa}+ HPLC purity · batch COA; independently verified by HPLC and LC-MS before release; LC-MS confirmed; residual moisture < 3.0{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} (Karl Fischer); every batch tested; third-party verified 99{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} purity.
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-20

Quantity: 2 mg / vial
Form: No DAC

£20.00per mg

£39.99per pack

View Analysis Buy Now

Product & testing details

Supplier: UK Peptides (ukpeptides.com)
Vials per pack: 1
Price per vial: £39.99
Listing last checked: 2026-09-20 09:20:11

Evidence status: Testing claimed
Manufacturer statement: "99.8{4126ccafc2fa8f847ceaeb6a91497cc67cd381373337e0df85dd9df95f3d94fa} HPLC verified"; "Specifications for this compound, independently verified by HPLC and LC-MS before release."; "Every batch is sent to an independent accredited lab for HPLC purity and LC-MS identity testing before it's released."
Laboratory: Not recorded
Certification body: Not recorded
Batch: Not recorded
Batch-specific report: Not established in this record
Report date: Not recorded
Evidence checked: 2026-09-20

What is CJC-1295?

CJC-1295 is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH). [S1][S2] The original clinical-development molecule incorporated four amino-acid substitutions plus a Drug Affinity Complex (DAC): a maleimide-containing C-terminal extension designed to bind covalently to circulating albumin and prolong exposure. [S1][S2] That DAC-bearing molecule is the form used in the published human pharmacology programme. A shorter 29-amino-acid form without the albumin-binding extension is also sold under the CJC-1295 name, but the human half-life and hormone-response data from the DAC studies should not be transferred to it. [S2]

The biggest accuracy issue on this page is nomenclature: 'CJC-1295 with DAC' and products marketed as 'CJC-1295 no DAC' are different chemical forms with different evidence bases. [S2]

CJC-1295 with DAC vs without DAC: do not treat them as the same compound

FDA's 2024 chemistry review separates CJC-1295 free base from CJC-1295 DAC as two different active moieties. [S2] The free-base form is a 29-amino-acid GHRH analogue with substitutions at positions 2, 8, 15 and 27. The DAC form adds an MPA-linked lysine at the C terminus; the maleimide group can form a stable adduct with albumin, which is the basis of the long-acting clinical molecule. [S1][S2] FDA concluded that the available clinical references appear to concern CJC-1295 DAC, while it did not identify studies establishing pharmacological activity for the non-DAC free base. [S2]

CJC-1295 DAC

The long-acting albumin-binding form used in the published human pharmacology studies.

Human evidence exists

CJC-1295 without DAC

The 29-amino-acid tetrasubstituted GHRH analogue without the albumin-binding extension. FDA did not identify a direct clinical evidence base for this active moiety.

Direct human evidence not established

Why it matters

The multi-day half-life reported in human studies belongs to the DAC clinical material. Applying it to a no-DAC product is an evidence error.

Key comparison point

Form	Structural distinction	Evidence position
CJC-1295 DAC	Tetrasubstituted GHRH(1-29) core plus albumin-binding MPA-Lys extension	Published human PK/PD studies
CJC-1295 without DAC	29-amino-acid tetrasubstituted GHRH analogue without the albumin-binding extension	No direct human clinical evidence established by FDA review
DAC salts	DAC active moiety supplied as acetate or TFA forms	Do not assume salt-specific clinical data unless the studied material is identified

Commercial use of the name 'Modified GRF (1-29)' or 'CJC-1295 no DAC' is inconsistent. Future product records should store the exact supplier label and analytical identity rather than infer chemistry from the product name.

Human pharmacology: sustained GH and IGF-1 increases with the DAC form

The best-known human study comprised two randomised, placebo-controlled, double-blind ascending-dose trials in healthy adults. [S3] In the single-dose study, 42 participants were enrolled: 35 received CJC-1295 DAC and seven received placebo. FDA's reconstruction identifies studied single doses of 30, 60, 125 and 250 micrograms per kilogram. [S2][S3] After one injection, mean GH concentrations increased roughly 2- to 10-fold for six days or more and mean IGF-1 increased roughly 1.5- to 3-fold for 9–11 days. [S3] The multiple-dose study enrolled 24 participants and found accumulation with repeated weekly or biweekly dosing, with mean IGF-1 remaining above baseline for up to 28 days. [S2][S3]

Growth hormone

Single-dose CJC-1295 DAC increased mean GH concentrations for six days or more in healthy adults.

Human PK/PD

IGF-1

Mean IGF-1 remained elevated for 9–11 days after a single dose and for up to 28 days during the repeated-dose study.

Human PK/PD

What was not tested

These studies measured hormone concentrations and pharmacokinetics, not muscle gain, fat loss, recovery, sleep or long-term clinical outcomes.

Outcome limitation

FDA's later review concluded that these healthy-volunteer studies do not establish effectiveness for growth hormone deficiency because they did not study patients with that condition or measure clinical endpoints such as body composition or growth. [S2]

Does CJC-1295 stop normal growth-hormone pulses?

A separate study examined 12 healthy men before and one week after a single subcutaneous CJC-1295 DAC dose of 60 or 90 micrograms per kilogram. [S4] GH pulse frequency and pulse magnitude were not significantly changed, while trough GH increased about 7.5-fold, mean GH increased 46% and IGF-1 increased 45%. [S4] The study therefore showed sustained elevation around preserved pulsatile secretion rather than complete replacement of pulses with a flat hormone signal.

This is a hormone-secretion study in 12 healthy men. It does not establish downstream physique, recovery or anti-ageing benefits.

Muscle gain and fat loss: the published human evidence does not answer those questions

CJC-1295 clearly changed GH and IGF-1 concentrations in healthy adults, but the published healthy-volunteer studies did not measure lean mass, fat mass, strength, exercise recovery or long-term weight change. [S2][S3][S4][S5] The only registered Phase 2 efficacy study targeted HIV-associated visceral obesity. It was terminated in 2006 and no trial results were posted. [S6] FDA's 2024 assessment therefore concluded that available human data did not establish clinical effectiveness for the nominated growth-hormone-deficiency use. [S2]

Muscle gain

No controlled published CJC-1295 human trial measuring lean-mass gain was identified in the reviewed evidence.

Human outcome gap

Fat loss

The registered visceral-obesity Phase 2 trial was terminated and has no posted efficacy results.

Unresolved Phase 2

Proteomic changes

An 11-man follow-up analysis found changes in several serum protein spots after CJC-1295, but this was biomarker research rather than a body-composition trial.

Biomarker study

A rise in GH or IGF-1 should not be used as a substitute endpoint for claims about muscle, fat, recovery or appearance.

The terminated Phase 2 visceral-obesity trial

NCT00267527 was a multicentre, randomised, placebo-controlled, double-blind Phase 2 study of CJC-1295 in people with HIV-associated visceral obesity. [S6] The current ClinicalTrials.gov record lists the study as terminated and shows no posted results. The registry currently displays enrolment of 120, while FDA's 2024 review and contemporaneous reporting say 192 participants had been enrolled and randomised when the programme was halted. [S2][S6][S7] FDA's review reports that one participant experienced an acute myocardial infarction about two hours after an eleventh weekly dose and died roughly one hour later; the attending physician's reported explanation was previously asymptomatic coronary disease with plaque rupture and occlusion. [S2] The study was terminated and the efficacy data were never published.

Trial feature	Verified information	Editorial treatment
Design	Randomised, placebo-controlled, double-blind Phase 2	Registered efficacy trial
Population	HIV-associated visceral obesity	Different from healthy-volunteer PK studies
Status	Terminated in 2006	No efficacy conclusion can be drawn
Results	No ClinicalTrials.gov results posted; no primary results publication identified	Do not infer benefit or failure
Participant death	Acute myocardial infarction after the 11th weekly dose; treating physician reportedly favoured underlying coronary disease as the explanation	Record the event without claiming drug causation

There is a material enrolment discrepancy: the current registry displays 120, while FDA's review says 192 had been randomised. Keep that discrepancy in research notes rather than silently choosing one figure.

CJC-1295 half-life: the multi-day figure applies to the DAC clinical material

In the published healthy-adult programme, the estimated terminal half-life of CJC-1295 DAC was 5.8–8.1 days after single dosing; FDA's reconstruction of the repeated-dose study reports mean estimates of 5.4–9.2 days in participants sampled for up to 14 days. [S2][S3] Drug concentrations remained measurable for roughly 10–13 days, and the albumin-binding DAC chemistry was designed to explain this prolonged exposure. [S1][S2] FDA also noted that a direct comparison proving how much the DAC extension lengthens half-life relative to the non-DAC free base was lacking. [S2]

Form	Human half-life evidence	What can be said
CJC-1295 DAC	5.8–8.1 days in the single-dose publication; 5.4–9.2 days in FDA's repeated-dose reconstruction	Direct human PK evidence
CJC-1295 without DAC	No validated human half-life established in the evidence reviewed	Do not reuse the DAC figure
Salt forms	Salt-specific clinical PK was not clearly identified	Preserve exact product form

The commonly repeated '6–8 day CJC-1295 half-life' is specifically a DAC-form finding.

CJC-1295 and ipamorelin: commonly paired, but not clinically validated as a combination

CJC-1295 and ipamorelin act through different upstream pathways: CJC-1295 is a GHRH analogue acting at the GHRH receptor, while ipamorelin is a ghrelin/growth-hormone-secretagogue receptor agonist. [S2] Both compounds have separate human pharmacology research, but no interventional human trial administering CJC-1295 and ipamorelin together was identified in the PubMed and ClinicalTrials.gov searches performed for this handoff. Commercially sold blends therefore should not be described as clinically validated combinations.

Do not provide blend ratios, timing or dosing protocols. The site can link internally to the existing Ipamorelin page for the component-specific evidence.

CJC-1295 dosage in research: what was actually studied?

The published human protocols describe CJC-1295 DAC study methodology, not a general or recommended dose. [S2][S3][S4] The single-dose study used 30, 60, 125 and 250 micrograms per kilogram. The repeated-dose study used 30 or 60 micrograms per kilogram every 14 days in two groups, and 20 or 30 micrograms per kilogram on days 0, 7 and 14 in two groups. [S2] The 12-man pulsatility study used a single 60 or 90 microgram-per-kilogram dose. [S4]

Research context	Protocol detail directly reported	What it means
Single-dose healthy-adult study	30, 60, 125 or 250 micrograms/kg subcutaneously	PK/PD and short-term safety methodology
Repeated-dose healthy-adult study	30 or 60 micrograms/kg on days 0 and 14, or 20 or 30 micrograms/kg on days 0, 7 and 14	Accumulation and hormone-response methodology
GH-pulsatility study	Single 60 or 90 micrograms/kg subcutaneous dose	Hormone-secretion physiology study
CJC-1295 without DAC	No validated human protocol established in the reviewed evidence	Do not transfer DAC dosing

These are historical clinical-research protocols for the DAC molecule. They are not personal-use instructions and must not be converted into a dosing schedule, reconstitution guide or price-per-dose calculation.

Side effects and safety: short-term human data exist, but they are limited

FDA's reconstruction of the healthy-volunteer studies provides more detail than the original abstracts. [S2] In the single-dose study, injection-site reactions occurred in about 70% of actively treated participants, headache in 63% versus 14% on placebo, diarrhoea in 43% of actively treated participants and systemic vasodilatory reactions such as flushing, warmth and transient hypotension in about 30%. [S2] Higher-dose groups generally had more adverse events. In the separate 12-man study, reported events included a dose-dependent increase in heart rate and transient injection-site redness/tenderness. [S2][S4] FDA's current compounding-safety page cites increased heart rate and systemic vasodilatory reaction among serious concerns and says available clinical data are limited. [S9]

Injection-site reactions

These were the most frequently reported events in the early DAC studies and were more severe or prolonged at higher doses.

Human trial finding

Vasodilatory reactions

Flushing, warmth and transient hypotension were reported in the early human studies.

Human trial finding

Heart rate

A dose-dependent heart-rate increase was reported in the 12-man pulsatility study.

Human trial finding

Long-term uncertainty

The clinical programme was small and short. FDA also highlights impurity, aggregation and immunogenicity concerns for compounded peptide products.

Evidence limited

Do not apply the DAC safety dataset automatically to no-DAC, acetate or TFA-labelled products. FDA specifically noted that the clinical material was not always identified precisely by salt form. [S2]

FDA review: several CJC-1295 forms were assessed separately

FDA's 2024 compounding review evaluated five related bulk substances: CJC-1295 free base, CJC-1295 acetate, CJC-1295 DAC free base, CJC-1295 DAC acetate and CJC-1295 DAC trifluoroacetate. [S2] FDA found substantial characterisation and safety gaps and concluded that the available healthy-volunteer studies did not demonstrate effectiveness for growth hormone deficiency. [S2] At the December 2024 advisory meeting, the committee voted 0–13 against placing the free base, DAC free base, DAC acetate and DAC TFA forms on the 503A Bulks List, and 1–12 against CJC-1295 acetate. [S8] FDA's current safety page continues to flag CJC-1295 for potential immunogenicity, peptide-impurity and API-characterisation concerns. [S9]

This is U.S. compounding-policy context, not a UK legal classification. No specific current MHRA CJC-1295 decision was independently verified in this research pass.

CJC-1295 and competitive sport

The World Anti-Doping Agency's 2026 Prohibited List explicitly names CJC-1295 among GHRH analogues under S2.2.4. [S10] S2 substances are prohibited at all times, both in and out of competition. Analytical laboratories have also published methods identifying CJC-1295 in seized pharmaceutical preparations. [S11]

Anti-doping status is separate from questions of clinical effectiveness or safety.

How to compare CJC-1295 research products

Future product comparison must start with identity. A vial labelled simply 'CJC-1295' is not enough to establish whether it contains the 29-amino-acid non-DAC form, the long-acting DAC molecule, or a particular salt. [S2] The comparison should therefore record exact form, labelled quantity, pack price, price per mg and testing evidence. Because FDA found naming inconsistencies and limited public impurity/aggregate characterisation, the testing tooltip should retain identity-method information where available rather than showing only a purity percentage. [S2]

DAC status

Record 'DAC', 'no DAC' or 'not clearly disclosed' before comparing products.

Exact form

Preserve free base, acetate or TFA labelling where disclosed rather than assuming all forms have the same mass basis.

Price per mg

Use labelled quantity as the value basis rather than any claimed human protocol.

Testing evidence

Distinguish independently verifiable identity/purity evidence, manufacturer COAs, unsupported claims and cases where no public evidence was located.

Do not rank a no-DAC product using the multi-day half-life or human GH/IGF-1 data from the DAC clinical programme.

Frequently asked questions

What is CJC-1295?

CJC-1295 is a synthetic growth hormone-releasing hormone analogue. The original clinical-development molecule included a Drug Affinity Complex that allowed it to bind albumin and remain in circulation for several days.

What is the difference between CJC-1295 with DAC and without DAC?

The DAC form adds an albumin-binding C-terminal modification to the 29-amino-acid GHRH analogue. The published human half-life and GH/IGF-1 studies used the DAC active moiety. FDA did not identify a comparable direct clinical evidence base for the non-DAC free-base form.

What benefits of CJC-1295 are actually proven in humans?

Human studies show that CJC-1295 DAC can raise circulating growth hormone and IGF-1 for several days. They do not establish muscle gain, fat loss, improved recovery, better sleep or anti-ageing outcomes.

What is the half-life of CJC-1295?

For the DAC clinical material, the published single-dose estimate was about 5.8–8.1 days, with FDA's repeated-dose reconstruction reporting about 5.4–9.2 days. A validated human half-life for the non-DAC form was not established in the evidence reviewed.

What doses of CJC-1295 have been studied?

Historical human CJC-1295 DAC studies used weight-based subcutaneous research protocols ranging from 20 to 250 micrograms/kg depending on the study and schedule. These are trial methods, not personal dosing instructions, and they do not establish a human protocol for no-DAC products.

What side effects were reported with CJC-1295?

Early DAC studies reported frequent injection-site reactions, headache, diarrhoea, flushing, warmth, transient hypotension and dose-related increases in heart rate. The studies were small and short, so reliable long-term frequencies are not established.

Did CJC-1295 increase growth hormone without removing normal pulses?

In a 12-man study, one dose increased trough and mean growth hormone and IGF-1 while pulse frequency and pulse magnitude remained broadly unchanged one week later.

Does CJC-1295 build muscle or reduce fat?

The published healthy-volunteer studies did not measure lean-mass gain or fat loss. A Phase 2 trial in HIV-associated visceral obesity was terminated and never posted efficacy results, so those outcome claims are not established.

Has CJC-1295 been studied with ipamorelin?

No interventional human study administering CJC-1295 and ipamorelin together was identified in the searches run for this handoff. The two compounds have separate mechanisms and separate human research records.

Why was the CJC-1295 Phase 2 trial terminated?

The HIV-associated visceral-obesity trial was halted after a participant had an acute myocardial infarction and died after the eleventh weekly dose. FDA's later review reports that the treating physician considered previously asymptomatic coronary artery disease with plaque rupture the most likely explanation. Causality from CJC-1295 was not established.

Is CJC-1295 banned in sport?

Yes under WADA rules. The 2026 Prohibited List explicitly names CJC-1295 among growth hormone-releasing hormone analogues in section S2.2.4, which is prohibited at all times.

Why should CJC-1295 products be separated by DAC status?

Because the DAC modification changes the molecule and its exposure profile. The multi-day human half-life data belong to the DAC form, so mixing DAC and no-DAC products without a clear label would make the comparison scientifically misleading.

Sources & methodology

We separate animal models, observational human studies and ongoing trials. Scientific evidence is assessed independently of future supplier documentation. How we verify testing →

Page updated: 19 September 2026Sources checked: 19 September 2026

Testing evidence in this comparison

Testing claimed: 3

What does CJC-1295 cost?

Lowest: £4.00 / mg · Median: £20.00 / mg · Highest: £20.00 / mg

CJC-1295 Research Peptides

Top Picks

Best Overall

CJC 1295 No DAC 10mgReta Research

CJC 1295 No DAC 10mg

Best Tested

CJC 1295 No DAC 10mgReta Research

CJC 1295 No DAC 10mg

Lowest Price per mg

CJC 1295 No DAC 10mgReta Research

CJC 1295 No DAC 10mg

Compare research products

CJC 1295 No DAC 10mgReta Research

CJC-1295 (with DAC) 2 mgUK Peptides (ukpeptides.com)

CJC-1295 (No DAC) 2 mgUK Peptides (ukpeptides.com)

What is CJC-1295?

CJC-1295 with DAC vs without DAC: do not treat them as the same compound

CJC-1295 DAC

CJC-1295 without DAC

Why it matters

Human pharmacology: sustained GH and IGF-1 increases with the DAC form

Growth hormone

IGF-1

What was not tested

Does CJC-1295 stop normal growth-hormone pulses?

Muscle gain and fat loss: the published human evidence does not answer those questions

Muscle gain

Fat loss

Proteomic changes

The terminated Phase 2 visceral-obesity trial

CJC-1295 half-life: the multi-day figure applies to the DAC clinical material

CJC-1295 and ipamorelin: commonly paired, but not clinically validated as a combination

CJC-1295 dosage in research: what was actually studied?

Side effects and safety: short-term human data exist, but they are limited

Injection-site reactions

Vasodilatory reactions

Heart rate

Long-term uncertainty

FDA review: several CJC-1295 forms were assessed separately

CJC-1295 and competitive sport

How to compare CJC-1295 research products

DAC status

Exact form

Price per mg

Testing evidence

Frequently asked questions

Sources & methodology

Testing evidence in this comparison

What does CJC-1295 cost?